...
机译:重建移植中的免疫抑制和耐受诱导最小化
Department of Plastic and Reconstructive Surgery Johns Hopkins University School of Medicine">(1);
Department of Plastic and Reconstructive Surgery Johns Hopkins University School of Medicine">(1);
Department of Plastic and Reconstructive Surgery Johns Hopkins University School of Medicine">(1);
Department of Plastic and Reconstructive Surgery Johns Hopkins University School of Medicine">(1);
Department of Plastic and Reconstructive Surgery Johns Hopkins Outpatient Center Johns Hopkins University School of Medicine">(3);
Department of Plastic and Reconstructive Surgery Johns Hopkins University School of Medicine">(1);
Vascularized composite allotransplantation; Hand transplantation; Face transplantation; Immunosuppression minimization; Tolerance induction; Bone marrow; Chimerism; Reconstructive transplantation;
机译:Alemtuzumab:在重建移植中最小化维持免疫抑制的关键?
机译:肾移植中的临床操作耐受性和免疫抑制最小化:我们站在哪里?
机译:移植耐受性的指纹图谱显示免疫抑制作用最小化的机会
机译:Fas介导的免疫抑制对异种肿瘤细胞移植的耐受性
机译:肾移植结果的回顾性分析:死者和活体供者肾脏移植患者中抗胸腺细胞球蛋白与Alemtuzumab的诱导免疫抑制作用。
机译:摘要QS37:联合供体骨髓移植和大剂量环磷酰胺治疗诱导重建移植后的免疫耐受延迟
机译:重建移植中免疫抑制和耐受性诱导的最小化